98. 好酸球性消化管疾患 Eosinophilic gastrointestinal disease Clinical trials / Disease details

臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135

diseases per page:

Showing 1 to 10 of 172 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05214599 (ClinicalTrials.gov)	September 2, 2023	3/1/2022	Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults ...	A Phase I/II, Multicenter, Double-blind, Parallel, Randomized Trial to Assess Pharmacokinetics, Effi ...	Eosinophilic Esophagitis	Drug: Budesonide Gel	Bazell Pharma AG	NULL	Not yet recruiting	18 Years	75 Years	All	36	Phase 2	NULL
2	NCT05774184 (ClinicalTrials.gov)	May 2023	7/3/2023	A Phase 2 Study of Barzolvolimab in Patients With Eosinophilic Esophagitis	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ba ...	Eosinophilic Esophagitis	Biological: barzolvolimab;Drug: Matching Placebo	Celldex Therapeutics	NULL	Not yet recruiting	18 Years	N/A	All	60	Phase 2	NULL
3	NCT05485155 (ClinicalTrials.gov)	April 2023	1/8/2022	Zemaira Eosinophilic Esophagitis Pilot Study	An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects With Eosinophilic Esophagitis ...	Eosinophilic Esophagitis	Drug: Alpha-proteinase inhibitor	Children's Hospital Medical Center, Cincinnati	CSL Behring;National Institutes of Health (NIH)	Not yet recruiting	18 Years	70 Years	All	15	Phase 2	NULL
4	NCT05608681 (ClinicalTrials.gov)	January 2023	19/10/2022	A Trial Evaluating EP-104IAR in Adults With Eosinophilic Esophagitis	A Phase 1b, Open Label Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104IAR in A ...	Eosinophilic Esophagitis	Drug: EP-104IAR	Eupraxia Pharmaceuticals Inc.	NULL	Not yet recruiting	18 Years	75 Years	All	24	Phase 1	NULL
5	NCT05634746 (ClinicalTrials.gov)	December 29, 2022	22/11/2022	24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)	Fluticasone Propionate Oral Disintegrating Tablet Formulation in Eosinophilic Esophagitis: A Randomi ...	Eosinophilic Esophagitis	Drug: APT-1011;Drug: Placebo oral tablet	Ellodi Pharmaceuticals, LP	NULL	Recruiting	18 Years	N/A	All	200	Phase 3	United States
6	NCT05606705 (ClinicalTrials.gov)	December 5, 2022	31/10/2022	A Study of Baked Milk Tolerance to Treat Eosinophilic Esophagtis	A Pilot Trial of Baked Milk Introduction in Patients With Milk-triggered Eosinophilic Esophagitis	Eosinophilic Esophagitis	Dietary Supplement: Baked Milk	Mayo Clinic	NULL	Enrolling by invitation	18 Years	90 Years	All	26	N/A	United States
7	NCT05594849 (ClinicalTrials.gov)	December 1, 2022	18/10/2022	Evaluation of Efficacy, Safety and Patient' Satisfaction of Therapeutic Switch From Off-Steroids to ...	Evaluation of Efficacy, Safety and Patient' Satisfaction of Therapeutic Switch From Off-Label Swallo ...	Eosinophilic Esophagitis	Drug: Budesonide Orodispersible Tablets (Jorveza)	Istituto Clinico Humanitas	NULL	Not yet recruiting	16 Years	80 Years	All	25		Italy
8	EUCTR2022-001294-31-DK (EUCTR)	22/11/2022	04/10/2022	Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ...	Eosinophilic esophagitis(EoE) is a rare, chronic inflammatory disorder triggered by an immune respon ...	Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Te ...	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 3	United States;Czechia;Slovakia;Greece;Finland;Spain;Austria;Israel;Italy;Canada;Belgium;Brazil;Denma ...
9	NCT05583227 (ClinicalTrials.gov)	November 10, 2022	13/10/2022	Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ...	Eosinophilic Esophagitis	Biological: Tezepelumab;Other: Placebo	AstraZeneca	Amgen	Recruiting	12 Years	80 Years	All	360	Phase 3	United States;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;Germany;Greece;I ...
10	JPRN-jRCT2031210574	28/07/2022	22/01/2022	A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY O ...	A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY O ...	eosinophilic esophagitis	All subjects will be administered CC-93538 at a dose of 360 mg SC once weekly.	Zhang Changliang	NULL	Pending	>= 12age old	<= 75age old	Both	22	Phase 3	Belgium;Australia;Argentina;Japan;United States of America;Canada;United Kingdom;Italy;Israel;Portug ...

First Previous1 2 3 4 5…18Next Last